Interactions of metal-metal-bonded antitumor active complexes with DNA fragments and DNA.

This Account summarizes the DNA binding properties of anticancer active dinuclear Rh, Re, and Ru compounds. The combined results of NMR spectroscopy, X-ray crystallography, and various biochemical tools provide incontrovertible evidence that dinuclear complexes are favorably poised to bind to purine nucleobases, DNA fragments, and double-stranded DNA. Moreover, direct DNA photocleavage in vitro is effected by dirhodium compounds in the presence of electron acceptors in solution or directly attached to the dirhodium core. This research has provided valuable insight in the interactions of dinuclear compounds with DNA, knowledge that is an excellent backdrop for rational design of promising dinuclear drugs.

[1]  M. Prater,et al.  A quadruply-bonded dirhenium complex bridged by two N1/N6 adenate ligands , 1998 .

[2]  J. Swarts,et al.  Cytotoxicity of a series of water-soluble mixed valent diruthenium tetracarboxylates. , 2002, Anticancer research.

[3]  C. Turro,et al.  Direct DNA photocleavage by a new intercalating dirhodium(II/II) complex: comparison to Rh2(mu-O2CCH3)4. , 2004, Inorganic chemistry.

[4]  D. L. Ward,et al.  A Novel Dirhodium Compound with Neutral, Bridging 9-Ethyladenine Ligands. , 1997, Inorganic chemistry.

[5]  D. Russell,et al.  Binding of DNA purine sites to dirhodium compounds probed by mass spectrometry. , 2004, Inorganic chemistry.

[6]  J. Bear,et al.  Mechanism of action of tetra-mu-carboxylatodirhodium(II) in L1210 tumor suspension culture. , 1979, Cancer research.

[7]  C. Turro,et al.  Effect of equatorial ligands of dirhodium(II,II) complexes on the efficiency and mechanism of transcription inhibition in vitro. , 2004, Inorganic chemistry.

[8]  N. Katsaros,et al.  The interaction of Rh(II) and Rh(III) with DNA. , 1990, Journal of inorganic biochemistry.

[9]  C. Turro,et al.  Photocytotoxicity of a new Rh2(II,II) complex: increase in cytotoxicity upon irradiation similar to that of PDT agent hematoporphyrin. , 2005, Inorganic chemistry.

[10]  Bernhard Lippert,et al.  Cisplatin : chemistry and biochemistry of a leading anticancer drug , 2006 .

[11]  S. Zyngier,et al.  Antitumor effects of rhodium (II) citrate in mice bearing Ehrlich tumors. , 1989, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[12]  G. Christou,et al.  N7, O6 bridging 9-ethylguanine (9-EtGH) groups in dinuclear metal–metal bonded complexes with bond orders of one, two or four , 1996 .

[13]  G. Christou,et al.  New Metal-Binding Mode for Adenine: A Bidentate (N6,N7) Bridging Mode in the Complex [Mo2(O2CCHF2)2(9-EtAH)2(MeCN)2](BF4)2.cntdot.2MeCN , 1994 .

[14]  M. Sundaralingam,et al.  Structure of the anti-cancer drug complex tetrakis (mu-acetato)-bis(1-methyladenosine)dirhodium(II) monohydrate. , 1991, Acta Crystallographica Section C: Crystal Structure Communications.

[15]  J. Bear,et al.  Studies of Rhodium(II) Carboxylates as Potential Antitumor Agents 1 , 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[16]  K. Dunbar,et al.  Novel binding interactions of the DNA fragment d(pGpG) cross-linked by the antitumor active compound tetrakis(mu-carboxylato)dirhodium(II,II). , 2003, Journal of the American Chemical Society.

[17]  J. C. Belchior,et al.  Controlled release of rhodium (II) carboxylates and their association complexes with cyclodextrins from hydroxyapatite matrix. , 2002, Biomaterials.

[18]  C. Turro,et al.  Inhibition of transcription in vitro by anticancer active dirhodium(II) complexes. , 2003, Inorganic chemistry.

[19]  D. L. Ward,et al.  REACTIONS OF DNA PURINES WITH DIRHODIUM FORMAMIDINATE COMPOUNDS THAT DISPLAY ANTITUMOR BEHAVIOR , 1999 .

[20]  A. Merbach,et al.  High-pressure proton NMR study of acetonitrile exchange kinetics on [Rh2(CH3CN)10]4+ and 17O NMR investigation of aqueous solutions of [Rh2(H2O)10]4 + , 1993 .

[21]  S. Gangopadhyay,et al.  Adenine and adenosine derivatives of tetraacetatodiruthenium (II,III) cation , 1997 .

[22]  C. Turro,et al.  DNA cleavage by photogenerated Rh(2)(O(2)CCH(3))(4)(H(2)O)(2)(+). , 2001, Inorganic Chemistry.

[23]  T. Thompson,et al.  Studies of rhenium carboxylates as antitumor agents. Part II. Antitumor studies of bis (mu-propionato) diaquotetrabromodirhenium (III) in tumor-bearing mice. , 1983, Methods and findings in experimental and clinical pharmacology.

[24]  B. Espósito,et al.  Rh2(CF3CONH)4: The First Biological Assays of a Rhodium (II) Amidate , 1997, Metal-based drugs.

[25]  B. Lippert.  Alterations of Nucleobase pKa Values upon Metal Coordination: Origins and Consequences , 2005 .

[26]  D. Duś,et al.  Properties of rhodium (II) complexes having cytostatic activity , 1996 .

[27]  Z. Ciunik,et al.  Tetraacetatodirhodium(II) complexes with tris(methoxyphenyl)phosphines, their reactivity, structure, and antitumor activity , 2001 .

[28]  E. Sherwood,et al.  The metabolism of rhodium(II) acetate in tumor-bearing mice. , 1976, Cancer research.

[29]  G. Christou,et al.  Binding of 2,2'-bipyridine to the dirhodium(II) tetraacetate core: unusual structural features and biological relevance of the product Rh2(OAc)4(bpy) , 1991 .

[30]  E. Freisinger,et al.  Diplatinum(III) complexes with bridging 1-methylcytosinate ligands and variable axial ligands, including guanine nucleobases , 2002 .

[31]  E. Sherwood,et al.  Hydrophobicity of several rhodium(II) carboxylates correlated with their biologic activity. , 1977, Journal of medicinal chemistry.

[32]  K. Dunbar,et al.  Covalent binding and interstrand cross-linking of duplex DNA by dirhodium(II,II) carboxylate compounds. , 2005, Biochemistry.

[33]  P. Piraino,et al.  Antitumor effect of the new rhodium (II) complex: Rh2 (form)2 (O2 CCF3)2 (H2O)2 (form = N,N'-di-p-tolyl formamidinate). , 1990, Journal of chemotherapy.

[34]  Jan Reedijk,et al.  New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Dunbar,et al.  Unprecedented head-to-head conformers of d(GpG) bound to the antitumor active compound tetrakis (mu-carboxylato)dirhodium(II,II). , 2003, Journal of the American Chemical Society.

[36]  K. Aoki,et al.  Interligand interactions affecting specific metal bonding to nucleic acid bases: the tetrakis(μ-trifluoroacetamidato)dirhodium(II)–cytosine system. Crystal structures of [Rh2(CF3CONH)4(cytosine)] and [Rh2(CF3CONH)4(1-methylcytosine)2]·2H2O , 2001 .

[37]  Stephen J Lippard,et al.  Cisplatin and related anticancer drugs: recent advances and insights. , 2004, Metal ions in biological systems.

[38]  G. Christou,et al.  Reaction of 2,2'−bipyridine (bpy) with dirhodium carboxylates : mono-bpy products with variable chelate binding modes and insights into the reaction mechanism , 1993 .

[39]  E. Zangrando,et al.  Axial guanine binding to a diplatinum(III) core , 2001 .

[40]  Kazuko Matsumoto,et al.  The reaction of 2'-deoxyribonucleoside with the α-pyrrolidonate-bridged Pt(III) dinuclear complex , 2002 .

[41]  M. L. Smith,et al.  Rhodium (II) butyrate: a potential anticancer drug with cell cycle phase-specific effects in HeLa cells. , 1980, Journal of the National Cancer Institute.

[42]  G. Tresoldi,et al.  Interactions of the Rh24+ formamidinate complex Rh2(μ-form)2(μ-O2CCF3)2(H2O)2 (form=N, N′-di-p-tolylformamidinate anion)with nucleobases and nucleosides , 1993 .

[43]  K. Dunbar,et al.  Structural evidence for monodentate binding of guanine to the dirhodium(II,II) core in a manner akin to that of cisplatin , 2003 .

[44]  S. Lippard,et al.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.

[45]  K. Aoki,et al.  Interligand interactions affecting specific metal bonding to nucleic acid bases. A case of [Rh2(OAc)4], [Rh2(HNOCCF3)4], and [Rh2(OAc)2(HNOCCF3)2] toward purine nucleobases and nucleosides , 2002 .

[46]  H. Gray,et al.  Interaction of Rhodium(II) carboxylates with molecules of biologic importance. , 1975, Cancer chemotherapy reports.

[47]  N. Katsaros,et al.  REACTIONS OF THE RHODIUM TRIFLUOROACETATE DIMER WITH NUCLEOSIDES AND NUCLEOTIDES , 1996 .

[48]  M. Stubbs,et al.  Interactions of metallopharmaceuticals with DNA. , 1996, Metal ions in biological systems.

[49]  N. Farrell.  Adenine and adenosine derivatives of rhodium acetate , 1981 .

[50]  C. Turro,et al.  DNA binding and photocleavage in vitro by new dirhodium(II) dppz complexes: correlation to cytotoxicity and photocytotoxicity. , 2004, Inorganic chemistry.

[51]  J. Asara,et al.  Evidence for Binding of Dirhodium Bis-Acetate Units to Adjacent GG and AA Sites on Single-Stranded DNA , 2000 .

[52]  N. Hadjiliadis,et al.  Interactions of tetrakis-µ-acetato-dirhodium(II) with adenine nucleosides and nucleotides , 1979 .

[53]  A. D. de Souza,et al.  Water-soluble rhodium(II) carboxylate adducts: cytotoxicity of the new compounds. , 1996, Journal of inorganic biochemistry.

[54]  G. Christou,et al.  Structural Evidence for a New Metal-Binding Mode for Guanine Bases: Implications for the Binding of Dinuclear Antitumor Agents to DNA , 1994 .